Renaissance Technologies’s Kiora Pharmaceuticals KPRX Stock Holding History

Renaissance Technologies’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,200	Closed	-$41.8K	–	3493
2025 Q4	$41.8K	Buy	21,200 +8,800	+71%	+$20.1K	﹤0.01%	3100
2025 Q3	$34.5K	Buy	+12,400	New	+$34.1K	﹤0.01%	3388
2024 Q2	–	Sell	-1,851	Closed	-$12K	–	3759
2024 Q1	$12K	Sell	1,851 -227	-11%	-$1.27K	﹤0.01%	3619
2023 Q4	$10K	Buy	+2,078	New	+$10.8K	﹤0.01%	3642
2022 Q3	–	Sell	-116	Closed	-$20K	–	4248
2022 Q2	$20K	Sell	116 -144	-55%	-$24.1K	﹤0.01%	4118
2022 Q1	$58K	Buy	+260	New	+$68K	﹤0.01%	3887
2021 Q3	–	Sell	-251	Closed	-$328K	–	3663
2021 Q2	$328K	Sell	251 -156	-38%	-$242K	﹤0.01%	3118
2021 Q1	$730K	Buy	+407	New	+$887K	﹤0.01%	2750
2020 Q3	–	Sell	-154	Closed	-$267K	–	3530
2020 Q2	$267K	Buy	154 +1	+0.7%	+$1.88K	﹤0.01%	3081
2020 Q1	$287K	Buy	153 +62	+68%	+$133K	﹤0.01%	2995
2019 Q4	$329K	Buy	+91	New	+$177K	﹤0.01%	3046

Other funds holding KPRX

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies's KPRX Position: Q1 2026 in Review

Renaissance Technologies sold out of Kiora Pharmaceuticals (KPRX) in Q1 2026, closing a stake of 21,200 shares — an estimated $41.8K sold.

Renaissance Technologies first reported a position in KPRX in Q4 2019 and held it in 11 quarters. The position peaked at $730K in Q1 2021. 18 funds tracked by Wall St. Rank hold KPRX as of Q1 2026.

Renaissance Technologies reported no remaining Kiora Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Renaissance Technologies sold 21,200 Kiora Pharmaceuticals shares in Q1 2026, an estimated $41.8K.
Renaissance Technologies first reported a position in Kiora Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Renaissance Technologies's Kiora Pharmaceuticals position peaked at $730K in Q1 2021.
18 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.